It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Microfibril-associated glycoprotein 4 (MFAP4) is an extracellular matrix protein belonging to the fibrinogen-related protein superfamily. MFAP4 is produced by vascular smooth muscle cells and is highly enriched in the blood vessels of the heart and lung, where it is thought to contribute to the structure and function of elastic fibers. Genetic studies in humans have implicated MFAP4 in the pathogenesis of Smith-Magenis syndrome, in which patients present with multiple congenital abnormalities and mental retardation, as well as in the severe cardiac malformation left-sided congenital heart disease. Comprehensive genetic analysis of the role of MFAP4 orthologues in model organisms during development and tissue homeostasis is however lacking. Here, we demonstrate that zebrafish mfap4 transcripts are detected embryonically, resolving to the macrophage lineage by 24 h post fertilization. mfap4 null mutant zebrafish are unexpectedly viable and fertile, without ostensible phenotypes. However, tail fin amputation assays reveal that mfap4 mutants have reduced numbers of macrophages, with a concomitant increase in neutrophilic granulocytes, although recruitment of both cell types to the site of injury was unaffected. Molecular analyses suggest that loss of Mfap4 alters the balance between myeloid and lymphoid lineages during both primitive and definitive haematopoiesis, which could significantly impact the downstream function of the immune system.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Agency for Science, Technology and Research (A*STAR), Institute of Medical Biology, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
2 Agency for Science, Technology and Research (A*STAR), Skin Research Institute of Singapore, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
3 Nanyang Technological University, Clinical Sciences Building, Lee Kong Chian School of Medicine, Singapore, Singapore (GRID:grid.59025.3b) (ISNI:0000 0001 2224 0361)
4 Agency for Science, Technology and Research (A*STAR), Institute of Medical Biology, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); Engine Biosciences, Singapore, Singapore (GRID:grid.185448.4)
5 Agency for Science, Technology and Research (A*STAR), Institute of Medical Biology, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); Nanyang Technological University, Clinical Sciences Building, Lee Kong Chian School of Medicine, Singapore, Singapore (GRID:grid.59025.3b) (ISNI:0000 0001 2224 0361)